KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Non-Current Deffered Revenue (2016 - 2017)

Vertex Pharmaceuticals (VRTX) has 9 years of Non-Current Deffered Revenue data on record, last reported at $1.7 million in Q4 2017.

  • For Q4 2017, Non-Current Deffered Revenue fell 73.97% year-over-year to $1.7 million; the TTM value through Dec 2017 reached $1.7 million, down 73.97%, while the annual FY2017 figure was $1.7 million, 73.97% down from the prior year.
  • Non-Current Deffered Revenue reached $1.7 million in Q4 2017 per VRTX's latest filing, down from $2.9 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $90.3 million in Q1 2013 and bottomed at $1.7 million in Q4 2017.
  • Average Non-Current Deffered Revenue over 5 years is $28.1 million, with a median of $19.3 million recorded in 2015.
  • Peak YoY movement for Non-Current Deffered Revenue: fell 22.28% in 2013, then tumbled 73.97% in 2017.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $49.5 million in 2013, then crashed by 43.78% to $27.8 million in 2014, then tumbled by 65.07% to $9.7 million in 2015, then tumbled by 31.73% to $6.6 million in 2016, then crashed by 73.97% to $1.7 million in 2017.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $1.7 million in Q4 2017, $2.9 million in Q3 2017, and $4.2 million in Q2 2017.